C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy.

Abstract

In this pilot study, results indicate that acetate PET holds promise for response assessment of prostate cancer bone metastases and is complementary to FDG PET in bone metastasis detection.

Full Text

DOI - (DOI)
Swets Information Services - full-text online
Ovid Technologies, Inc. - full-text online
Lippincott Williams & Wilkins - full-text online

Subjects

Similar articles

11C-acetate PET imaging of prostate cancer. (2002-02-18)
PET in the management of urologic malignancies. (2004-10-18)
The role of (18)F-fluoride PET-CT in the detection of bone metastases in patients with breast, lung and prostate carcinoma: a comparison with FDG PET/CT and (99m)Tc-MDP bone scan. (2013-02-02)
The Value of 18F-FLT PET for Detecting Second Primary Cancers and Distant Metastases in Head and Neck Cancer Patients. (2013-02-28)
Detecting metastatic pelvic lymph nodes by 18F-2-deoxyglucose positron emission tomography in patients with prostate-specific antigen relapse after treatment for localized prostate cancer. (2003-05-12)
Q Fever masquerading as prostate cancer metastases. (2012-04-05)
Evaluation of Response to Therapy in a Patient with Lung Cancer: Correlation of Sclerotic Bone Lesions with F 18 FDG PET/CT and Bone Scintigraphy. (2011-04-01)
Comparison of FDG PET/CT and Gadolinium-Enhanced MRI for the Detection of Bone Metastases in Patients With Cancer: A Meta-analysis. (2013-03-28)
11C-acetate PET imaging of prostate cancer: detection of recurrent disease at PSA relapse. (2003-04-07)

Authors

Publication date

2011-02-02

Journal

Clinical nuclear medicine
Clin Nucl Med (1536-0229)

Journal topics

Language

Eng.

Copyright

Division of Oncology, Department of Medicine, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA. evanyu [at] uw.edu

Release reference

Clin Nucl Med. 2011 Mar;36(3):192-8

Related books

Español | English

© Galenicom 1999-2013